.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,715,746

« Back to Dashboard

Details for Patent: 8,715,746

Title:Sodium thiosulfate-containing pharmaceutical compositions
Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Inventor(s): Sherman; Craig (Scottsdale, AZ), Smith; Catherine Marie (Grafton, WI), Wirtz; Kevin Robert (Belgium, WI), Schulze; Erich (Mission Viejo, CA)
Assignee: Hope Medical Enterprises, Inc. (Scottsdale, AZ)
Filing Date:Jun 26, 2013
Application Number:13/927,241
Claims:1. A method for preparing pharmaceutical grade sodium thiosulfate pentahydrate comprising: a) contacting sodium sulfite with sulfur in an aqueous solvent at a temperature of between about 90.degree. C. and about 110.degree. C., wherein the pH after about 4 hours of the resulting mixture is from about 7 to about 9; b) cooling the mixture to between about 15.degree. C. and about 25.degree. C.; c) adding a base to the mixture until the pH of the mixture is basic; d) filtering the mixture to yield a solution; e) distilling the solution at between about 50.degree. C. and about 100.degree. C. to a gravity of between about 1.20 to about 1.70; f) contacting the solution with activated carbon at between about 45.degree. C. and about 55.degree. C.; g) filtering the solution to remove the activated carbon; h) cooling the solution to between about 15.degree. C. and about 25.degree. C. and adding a seed crystal of sodium thiosulfate pentahydrate; i) cooling the solution to between about 0.degree. C. and about 10.degree. C. and filtering the solution; and j) drying the sodium thiosulfate pentahydrate at about 35.degree. C. until the water content of the sodium thiosulfate pentahydrate is between about 34% weight and about 36.8% weight.

2. The method of claim 1, wherein the contacting of the sodium sulfite and the sulfur is conducted under an inert atmosphere.

3. The method of claim 1, wherein the sodium sulfite and the sulfur are contacted in water.

4. The method of claim 1, wherein the sodium sulfite and the sulfur are contacted in water for about 4 hours.

5. The method of claim 1, wherein the base is sodium hydroxide.

6. The method of claim 1, wherein the pH of the mixture is about 6.6 when the mixture is cooled to between about 15.degree. C. and about 25.degree. C.

7. The method of claim 1, wherein the solution is distilled to a specific gravity between about 1.30 and about 1.60.

8. The method of claim 1, wherein the solution is distilled to a specific gravity between about 1.40 and about 1.50.

9. The method of claim 1, wherein the solution is distilled to a specific gravity between about 1.40 and about 1.45.

10. The method of claim 1, wherein the solution is contacted with activated carbon for at least about 30 minutes.

11. The method of claim 1, wherein the solution with the added seed crystal of sodium thiosulfate pentahydrate is cooled to between about 0.degree. C. and about 10.degree. C. and stirred for about 15 hours.

12. The method of claim 1, wherein the pharmaceutical grade sodium thiosulfate pentahydrate contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.01% by weight of carbonate, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% of sulfite, contains no greater than about 0.5% of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the pharmaceutical grade sodium thiosulfate pentahydrate at 25.degree. C. is colorless and has a pH between about 6.0 and about 8.0, and wherein the pharmaceutical grade sodium thiosulfate pentahydrate is odorless crystals.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc